HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cummings, J. L. Articles by Back, C. Search for Related Content PubMed PubMed Citation Articles by Cummings, J. L. Articles by Back, C.

The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease

A variety of neuropsychiatric symptoms occur in Alzheimer's disease (AD) including agitation, psychosis, depression, apathy, disinhibition, anxiety, purposeless behavior, and disorders of sleep and appetite. Neuropsychiatric symptoms have been related to cholinergic deficiency and improve after treatment with cholinomimetic agents. Cholinergic drugs are unique among psychotropic agents in exerting disease-specific and broad-spectrum effects. These observations provide the basis for the cholinergic hypothesis of the neuropsychiatric symptoms of AD, suggesting that the cholinergic deficit of AD contributes to the neuropsychiatric symptoms of AD and that cholinomimetic therapy ameliorates the behavioral disturbances accompanying AD.

Key Words: Alzheimer's Disease • Cholinergic Hypothesis • Cholinesterase Inhibitors • Neuropsychiatry • Psychosis • Agitation • Nucleus Basalis

This article has been cited by other articles:

				A. Berson, M. Knobloch, M. Hanan, S. Diamant, M. Sharoni, D. Schuppli, B. C. Geyer, R. Ravid, T. S. Mor, R. M. Nitsch, et al. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology Brain, January 1, 2008; 131(1): 109 - 119. [Abstract] [Full Text] [PDF]

				H.-W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang Therapeutic approaches to Alzheimer's disease Brain, November 1, 2006; 129(11): 2840 - 2855. [Abstract] [Full Text] [PDF]

				K. R. Birikh, E. H. Sklan, S. Shoham, and H. Soreq Interaction of "readthrough" acetylcholinesterase with RACK1 and PKCbeta II correlates with intensified fear-induced conflict behavior PNAS, January 7, 2003; 100(1): 283 - 288. [Abstract] [Full Text] [PDF]

				M. K. P. Lai, O. -F. Lai, J. Keene, M. M. Esiri, P. T. Francis, T. Hope, and C. P.L.-H. Chen Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex Neurology, September 11, 2001; 57(5): 805 - 811. [Abstract] [Full Text] [PDF]

				H. Feldman, S. Gauthier, J. Hecker, B. Vellas, P. Subbiah, and E. Whalen A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology, August 28, 2001; 57(4): 613 - 620. [Abstract] [Full Text] [PDF]

				S. L. Minger, M. M. Esiri, B. McDonald, J. Keene, J. Carter, T. Hope, and P. T. Francis Cholinergic deficits contribute to behavioral disturbance in patients with dementia Neurology, November 28, 2000; 55(10): 1460 - 1467. [Abstract] [Full Text] [PDF]

				T BABIC;, P. T FRANCIS, A. M PALMER, M. SNAPE, and G. K WILCOCK The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol. Neurosurg. Psychiatry, October 1, 1999; 67(4): 558 - 558. [Full Text] [PDF]

				C. C. Meltzer Neuropharmacology and Receptor Studies in the Elderly J Geriatr Psychiatry Neurol, October 1, 1999; 12(3): 137 - 149. [Abstract] [PDF]